Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Sierra Oncology (SRRA) News Today

Sierra Oncology logo
Sierra Oncology Inc.
Sierra Coupon for October
Sierra Oncology (NASDAQ: SRRA)
Sierra Leone
Interventional Oncology Global Market - Forecast To 2029
Sierra Oncology hits 52w high – but will it continue?
Sierra Oncology, Inc. stock logo
Sierra Oncology, Inc. (NASDAQ:SRRA) Given Consensus Rating of "Hold" by Brokerages
Shares of Sierra Oncology, Inc. (NASDAQ:SRRA - Get Rating) have received an average rating of "Hold" from the six brokerages that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company
Sierra Oncology, Inc. stock logo
-$0.95 Earnings Per Share Expected for Sierra Oncology, Inc. (NASDAQ:SRRA) This Quarter
Equities research analysts forecast that Sierra Oncology, Inc. (NASDAQ:SRRA - Get Rating) will announce earnings of ($0.95) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sierra Oncology's earnings, with the highest EPS estimate c
Sierra Oncology, Inc. stock logo
Sierra Oncology (NASDAQ:SRRA) Downgraded to Hold at Zacks Investment Research
Zacks Investment Research cut Sierra Oncology from a "buy" rating to a "hold" rating in a research note on Wednesday.
Sierra Oncology, Inc. stock logo
Short Interest in Sierra Oncology, Inc. (NASDAQ:SRRA) Decreases By 55.9%
Sierra Oncology, Inc. (NASDAQ:SRRA - Get Rating) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 1,010,000 shares, a decline of 55.9% from the April 15th total of 2,290,000 shares. Based on an average daily volume of 595,100 shares, the days-to-cover ratio is currently 1.7 days.
Sierra Oncology, Inc. stock logo
Sierra Oncology, Inc. (NASDAQ:SRRA) Receives Consensus Rating of "Hold" from Analysts
Sierra Oncology, Inc. (NASDAQ:SRRA - Get Rating) has been assigned a consensus rating of "Hold" from the six ratings firms that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the c
Analyst Ratings for Sierra Oncology
Sierra Oncology Stock Is Soaring: Here's Why
Why Is Sierra Oncology (SRRA) Stock Up Today?
Sierra Oncology, Inc. stock logo
Oppenheimer Increases Sierra Oncology (NASDAQ:SRRA) Price Target to $45.00
Oppenheimer upped their price objective on shares of Sierra Oncology from $38.00 to $45.00 in a report on Monday.
Sierra Oncology Non-GAAP EPS of -$1.44
Sierra Oncology Reports 2021 Year End Results
Get Sierra Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter.

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

SRRA Media Mentions By Week

SRRA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SRRA
News Sentiment

0.00

0.48

Average
Medical
News Sentiment

SRRA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SRRA Articles
This Week

0

0

SRRA Articles
Average Week

Get Sierra Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:SRRA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners